Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2191]
News [5868]
Articles [116]
Editorials [31]
Conferences [186]
elearning [22]
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small...
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )
2 May 2023
The use of IORT at Universitätsmedizin Mannheim hospital
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany
The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )
2 May 2023
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
26 Apr 2023
Breast and emerging indications for IORT
Dr David Martinez Perez - AUNA, Lima, Peru
Breast and emerging indications for IORT ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023
The advantages of IORT for early breast cancer treatment
Dr David Martinez Perez - AUNA, Lima, Peru
The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )
26 Apr 2023
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in...
Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours ( Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA )
26 Apr 2023
VT3989 is safe and well tolerated in patients with advanced malignant...
Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA
VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )
25 Apr 2023
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...
Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )
25 Apr 2023
Durable effect of imatinib and metronomic chemotherapy with capecitabine in...
Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma ( Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan )
21 Apr 2023
Cancer Care in Older Adults and Special Population
Dr Don Dizon - Rhode Island Hospital, Rhode Island, USA
Cancer Care in Older Adults and Special Population ( Dr Don Dizon - Rhode Island Hospital, Rhode Island, USA )
20 Apr 2023
Why tumour markers are not recommended as screening tests
Dr Frederic Ting - Riverside Medical Center, Bacolod, Philippines
Why tumour markers are not recommended as screening tests ( Dr Frederic Ting - Riverside Medical Center, Bacolod, Philippines )
20 Apr 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation